{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:08:56Z","timestamp":1787069336055,"version":"build-2736575974"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2015,7,14]],"date-time":"2015-07-14T00:00:00Z","timestamp":1436832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100002997","name":"Dutch Kidney Foundation","doi-asserted-by":"publisher","award":["KFB 11\u00b7007"],"award-info":[{"award-number":["KFB 11\u00b7007"]}],"id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002997","name":"Dutch Kidney Foundation","doi-asserted-by":"publisher","award":["IP 10\u00b722"],"award-info":[{"award-number":["IP 10\u00b722"]}],"id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002997","name":"Dutch Kidney Foundation","doi-asserted-by":"publisher","award":["KBSO 11\u00b7019"],"award-info":[{"award-number":["KBSO 11\u00b7019"]}],"id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002997","name":"Dutch Kidney Foundation","doi-asserted-by":"publisher","award":["C09\u00b72313"],"award-info":[{"award-number":["C09\u00b72313"]}],"id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016298","name":"ERA-EDTA","doi-asserted-by":"publisher","award":["ERA STF 138\u20132013"],"award-info":[{"award-number":["ERA STF 138\u20132013"]}],"id":[{"id":"10.13039\/501100016298","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,7,14]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Atypical haemolytic uraemic syndrome (aHUS) is associated with (genetic) alterations in alternative complement pathway. Nevertheless, comprehensive evidence that the complement system in aHUS patients is more prone to activation is still lacking. Therefore, we performed a thorough analysis of complement activation in acute phase and in remission of this disease. Complement activation patterns of the aHUS patients in acute phase and in remission were compared to those of healthy controls. Background levels of complement activation products C3b\/c, C3bBbP and terminal complement complex (TCC) were measured using enzyme-linked immunosorbent assay (ELISA) in ethylenediamine tetraacetic acid (EDTA) plasma. In vitro-triggered complement activation in serum samples was studied using zymosan-coating and pathway-specific assay. Furthermore, efficiencies of the C3b\/c, C3bBbP and TCC generation in fluid phase during spontaneous activation were analysed. Patients with acute aHUS showed elevated levels of C3b\/c (P &amp;lt; 0\u00b701), C3bBbP (P &amp;lt; 0\u00b70001) and TCC (P &amp;lt; 0\u00b70001) in EDTA plasma, while values of patients in remission were normal, compared to those of healthy controls. Using data from a single aHUS patient with complement factor B mutation we illustrated normalization of complement activation during aHUS recovery. Serum samples from patients in remission showed normal in vitro patterns of complement activation and demonstrated normal kinetics of complement activation in the fluid phase. Our data indicate that while aHUS patients have clearly activated complement in acute phase of the disease, this is not the case in remission of aHUS. This knowledge provides important insight into complement regulation in aHUS and may have an impact on monitoring of these patients, particularly when using complement inhibition therapy.<\/jats:p>","DOI":"10.1111\/cei.12426","type":"journal-article","created":{"date-parts":[[2014,7,31]],"date-time":"2014-07-31T04:09:11Z","timestamp":1406779751000},"page":"306-313","source":"Crossref","is-referenced-by-count":40,"title":["Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission"],"prefix":"10.1093","volume":"181","author":[{"given":"E B","family":"Volokhina","sequence":"first","affiliation":[{"name":"Department of Pediatric Nephrology, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Westra","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T J A M","family":"van der Velden","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N C A J","family":"van de Kar","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T E","family":"Mollnes","sequence":"additional","affiliation":[{"name":"Department of Immunology, Oslo University Hospital, Oslo, Norway"},{"name":"K. G. Jebsen IRC, University of Oslo, Oslo, Norway"},{"name":"Research Laboratory, Nordland Hospital, Bod\u00f8, Norway"},{"name":"Faculty of Health Sciences, University of Troms\u00f8, Troms\u00f8, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L P","family":"van den Heuvel","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Radboud University Medical Center, Nijmegen, the Netherlands"},{"name":"Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands"},{"name":"Department of Pediatric Nephrology, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,7,14]]},"reference":[{"key":"2021122010165942300_cei12426-bib-0001","first-page":"121","article-title":"A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome","volume":"70","author":"Westra","year":"2012","journal-title":"Neth J Med"},{"key":"2021122010165942300_cei12426-bib-0002","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00467-010-1556-4","article-title":"aHUS caused by complement dysregulation: new therapies on the horizon","volume":"26","author":"Waters","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"2021122010165942300_cei12426-bib-0003","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.molimm.2013.05.224","article-title":"Complement therapy in atypical haemolytic uraemic syndrome (aHUS)","volume":"56","author":"Wong","year":"2013","journal-title":"Mol Immunol"},{"key":"2021122010165942300_cei12426-bib-0004","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic\u2013uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"2021122010165942300_cei12426-bib-0005","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJM200104053441406","article-title":"Complement. First of two parts","volume":"344","author":"Walport","year":"2001","journal-title":"N Engl J Med"},{"key":"2021122010165942300_cei12426-bib-0006","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.addr.2011.05.010","article-title":"Advances in assay of complement function and activation","volume":"63","author":"Harboe","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"2021122010165942300_cei12426-bib-0007","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1182\/blood-2007-08-106153","article-title":"Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation","volume":"111","author":"Stahl","year":"2008","journal-title":"Blood"},{"key":"2021122010165942300_cei12426-bib-0008","doi-asserted-by":"crossref","first-page":"15650","DOI":"10.1074\/jbc.M900814200","article-title":"Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome","volume":"284","author":"Lehtinen","year":"2009","journal-title":"J Biol Chem"},{"key":"2021122010165942300_cei12426-bib-0009","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1136\/jmg.2004.019083","article-title":"Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome","volume":"41","author":"Fremeaux-Bacchi","year":"2004","journal-title":"J Med Genet"},{"key":"2021122010165942300_cei12426-bib-0010","doi-asserted-by":"crossref","first-page":"12966","DOI":"10.1073\/pnas.2135497100","article-title":"Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome","volume":"100","author":"Richards","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122010165942300_cei12426-bib-0011","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/S0140-6736(03)14742-3","article-title":"Familial haemolytic uraemic syndrome and an MCP mutation","volume":"362","author":"Noris","year":"2003","journal-title":"Lancet"},{"key":"2021122010165942300_cei12426-bib-0012","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/hmg\/ddi066","article-title":"Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32","volume":"14","author":"Esparza-Gordillo","year":"2005","journal-title":"Hum Mol Genet"},{"key":"2021122010165942300_cei12426-bib-0013","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome","volume":"108","author":"Caprioli","year":"2006","journal-title":"Blood"},{"key":"2021122010165942300_cei12426-bib-0014","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1182\/blood-2008-01-133702","article-title":"Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome","volume":"112","author":"Fremeaux-Bacchi","year":"2008","journal-title":"Blood"},{"key":"2021122010165942300_cei12426-bib-0015","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1182\/blood-2011-10-383281","article-title":"A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function","volume":"119","author":"Roumenina","year":"2012","journal-title":"Blood"},{"key":"2021122010165942300_cei12426-bib-0016","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00467-012-2183-z","article-title":"Novel C3 mutation p.Lys65Gln in aHUS affects complement factor H binding","volume":"27","author":"Volokhina","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"2021122010165942300_cei12426-bib-0017","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1073\/pnas.0603420103","article-title":"Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome","volume":"104","author":"Goicoechea de Jorge","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122010165942300_cei12426-bib-0018","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa0810739","article-title":"Thrombomodulin mutations in atypical hemolytic\u2013uremic syndrome","volume":"361","author":"Delvaeye","year":"2009","journal-title":"N Engl J Med"},{"key":"2021122010165942300_cei12426-bib-0019","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1182\/blood-2007-09-109876","article-title":"Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1\/CFHR3 deficiency","volume":"111","author":"Jozsi","year":"2008","journal-title":"Blood"},{"key":"2021122010165942300_cei12426-bib-0020","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/ng.2622","article-title":"DGKE and atypical HUS","volume":"45","author":"Quaggin","year":"2013","journal-title":"Nat Genet"},{"key":"2021122010165942300_cei12426-bib-0021","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic\u2013uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"key":"2021122010165942300_cei12426-bib-0022","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/MOH.0b013e32833cae86","article-title":"Atypical hemolytic uremic syndrome","volume":"17","author":"Kavanagh","year":"2010","journal-title":"Curr Opin Hematol"},{"key":"2021122010165942300_cei12426-bib-0023","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"6","author":"Loirat","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"2021122010165942300_cei12426-bib-0024","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2010030315","article-title":"Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome","volume":"21","author":"Dragon-Durey","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2021122010165942300_cei12426-bib-0025","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2013-12-547067","article-title":"Biomarkers of the alternative pathway and terminal complement activity at presentation confirms the clinical diagnosis of aHUS and differentiates aHUS from TTP","volume":"123","author":"Cataland","year":"2014","journal-title":"Blood"},{"key":"2021122010165942300_cei12426-bib-0026","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","article-title":"A simple salting out procedure for extracting DNA from human nucleated cells","volume":"16","author":"Miller","year":"1988","journal-title":"Nucleic Acids Res"},{"key":"2021122010165942300_cei12426-bib-0027","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1093\/ndt\/gfq010","article-title":"Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS)","volume":"25","author":"Westra","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"2021122010165942300_cei12426-bib-0028","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.molimm.2013.05.221","article-title":"An international serum standard for application in assays to detect human complement activation products","volume":"56","author":"Bergseth","year":"2013","journal-title":"Mol Immunol"},{"key":"2021122010165942300_cei12426-bib-0029","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.4049\/jimmunol.1200269","article-title":"The role of properdin in zymosan- and Escherichia coli-induced complement activation","volume":"189","author":"Harboe","year":"2012","journal-title":"J Immunol"},{"key":"2021122010165942300_cei12426-bib-0030","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1128\/iai.38.3.1279-1284.1982","article-title":"Inhibition of zymosan-induced alternative complement pathway activation by concanavalin A","volume":"38","author":"Smith","year":"1982","journal-title":"Infect Immun"},{"key":"2021122010165942300_cei12426-bib-0031","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.molimm.2006.06.020","article-title":"The role of complement in biomaterial-induced inflammation","volume":"44","author":"Nilsson","year":"2007","journal-title":"Mol Immunol"},{"key":"2021122010165942300_cei12426-bib-0032","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.imbio.2012.07.012","article-title":"Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis","volume":"217","author":"DeAngelis","year":"2012","journal-title":"Immunobiology"},{"key":"2021122010165942300_cei12426-bib-0033","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.molimm.2012.10.044","article-title":"Monitoring and modeling treatment of atypical hemolytic uremic syndrome","volume":"54","author":"Heinen","year":"2013","journal-title":"Mol Immunol"},{"key":"2021122010165942300_cei12426-bib-0034","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/asheducation-2011.1.15","article-title":"Atypical hemolytic uremic syndrome, genetic basis, and clinical manifestations","volume":"2011","author":"Kavanagh","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcei.12426","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/181\/2\/306\/41791378\/cei12426.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/181\/2\/306\/41791378\/cei12426.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T11:26:46Z","timestamp":1641036406000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/181\/2\/306\/6422172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,14]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,7,14]]},"published-print":{"date-parts":[[2015,7,14]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.12426","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,8]]},"published":{"date-parts":[[2015,7,14]]}}}